Digest Network Come funziona
Network
/
Società
F.
Non verificato

F. Hoffmann-La Roche Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaPubblicità/Marketing/Media/Comunicazione

134 comunicati stampa

Guarda tutti i comunicati
26/05/2026
Farmaceutica
Annunci Economici
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
06/05/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
29/04/2026
Farmaceutica
Annunci Economici
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
22/04/2026
Farmaceutica
Annunci Economici
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
21/04/2026
Farmaceutica
Annunci Economici
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
21/04/2026
Farmaceutica
Annunci Economici
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
12/04/2026
Farmaceutica
Annunci Economici
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0